Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene ROS1
Variant G2032R
Impact List missense
Protein Effect unknown
Gene Variant Descriptions ROS1 G2032R lies within the protein kinase domain of the Ros1 protein (UniProt.org). G2032R has been associated with resistance to Ros1 tyrosine kinase inhibitors in the context of ROS1 fusions in patients (PMID: 36135089, PMID: 25033171, PMID: 29477381), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, Jan 2024).
Associated Drug Resistance Y
Category Variants Paths

ROS1 mutant ROS1 G2032R

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_002944.3
gDNA chr6:g.117317184C>T
cDNA c.6094G>A
Protein p.G2032R
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
XM_011536051.3 chr6:g.117317187C>T c.6094G>A p.G2032R RefSeq GRCh38/hg38
NM_002944.2 chr6:g.117317184C>T c.6094G>A p.G2032R RefSeq GRCh38/hg38
NM_002944 chr6:g.117317184C>T c.6094G>A p.G2032R RefSeq GRCh38/hg38
XM_011536051.2 chr6:g.117317187C>T c.6094G>A p.G2032R RefSeq GRCh38/hg38
NM_002944.3 chr6:g.117317184C>T c.6094G>A p.G2032R RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ROS1 fusion ROS1 G2032R lung non-small cell carcinoma predicted - sensitive Repotrectinib Phase I Actionable In a Phase I/II trial (TRIDENT-1), Augtyro (repotrectinib) treatment resulted in a confirmed objective response rate of 59% (10/17) in patients with TKI-pretreated, ROS1 fusion-positive non-small cell lung cancer harboring ROS1 G2032R (PMID: 38197815; NCT03093116). 38197815
ROS1 fusion ROS1 G2032R Advanced Solid Tumor predicted - sensitive Repotrectinib Phase I Actionable In a Phase I (TRIDENT-1) trial, Augtyro (repotrectinib) treatment resulted in partial response in a patient with advanced solid tumor harboring ROS1 G2032R in the context of ROS1 fusion (J Clin Oncol 36, 2018 (suppl; abstr 2513); NCT03093116). detail...
ROS1 fusion ROS1 G2032R lung non-small cell carcinoma predicted - sensitive Taletrectinib Case Reports/Case Series Actionable In a Phase II trial (TRUST-I), Taletrectinib (DS6051b) treatment resulted in an objective response rate of 66.7% (8/12, all partial responses) in patients with non-small cell lung cancer harboring ROS1 fusions with secondary ROS1 G2032R mutations (PMID: 38822758; NCT04395677). 38822758
ROS1 fusion ROS1 G2032R lung non-small cell carcinoma predicted - sensitive NUV-520 Phase I Actionable In a Phase I trial (ARROS-1), NUV-520 treatment resulted in 6 partial responses among 12 patients with non-small cell lung cancer harboring a ROS1 fusion including a partial response in 5 of 7 patients harboring a ROS1 fusion with ROS1 G2032R (Eu J Cancer 2022 Vol 174, Supp 1:S6-S7; NCT05118789). detail...